Should Non-ST-Elevation Myocardial Infarction be Treated like ST-Elevation Myocardial Infarction With Shorter Door-to-Balloon Time?


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
15 01 2020
Historique:
received: 25 07 2019
revised: 14 10 2019
accepted: 16 10 2019
pubmed: 20 11 2019
medline: 23 4 2020
entrez: 20 11 2019
Statut: ppublish

Résumé

It is estimated that each year in the United States >780,000 persons will experience an acute coronary syndrome. Approximately 70% of these will have non-ST-elevation myocardial infarction (NSTEMI). Optimal timing of angiography in NSTEMI is a matter of debate. The aim of this retrospective analysis was to evaluate whether and how the timing of percutaneous coronary intervention (PCI) affects the 1-year rate of major adverse cardiac events (MACE) in patients presenting with NSTEMI. Within our PCI database, we identified 1550 patients who underwent PCI for NSTEMI. We then divided the population into 3 groups based on door-to-balloon time (D2BT) (group 1 = D2BT <90 minutes; group 2 = D2BT >90 minutes <24 hours; group 3 = D2BT >24 hours). Primary outcome was MACE, a composite of MI, death and target vessel revascularization (TVR), or TVR at 1 year. Baseline characteristics were heterogeneous among the 3 groups, with patients who underwent angiograms >24 hours from presentation being older with more cardiovascular co-morbidities. Patients with D2BT <90 minutes were more likely to present with cardiogenic shock and had higher troponin levels. In-hospital mortality was similar among the 3 groups, but 1-year MACE/TVR was significantly higher in groups 1 and 3, driven by worse mortality. In this large cohort of patients presenting with NSTEMI, patients who underwent PCI between 90 minutes to 24 hours from presentation had better 1-year outcomes but also had fewer co-morbidities and with significantly lower prevalence of cardiogenic shock and high troponin on presentation. Therefore, treatment selection bias makes causal inference concerning rapid revascularization and outcome unreliable. Randomized clinical trials are warranted to assess outcome of rapid revascularization in patients presenting with NSTEMI.

Identifiants

pubmed: 31740021
pii: S0002-9149(19)31158-0
doi: 10.1016/j.amjcard.2019.10.012
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

165-168

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Micaela Iantorno (M)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Evan Shlofmitz (E)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Toby Rogers (T)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia; National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.

Rebecca Torguson (R)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Paul Kolm (P)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Deepakraj Gajanana (D)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Nauman Khalid (N)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Yuefeng Chen (Y)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

William S Weintraub (WS)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia.

Ron Waksman (R)

Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, District of Columbia. Electronic address: ron.waksman@medstar.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH